This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Hepatic disease

Liver fibrosis

IL-33 (NF-HEV)

Patient and mouse studies suggest inhibiting IL-33 signaling could help treat liver fibrosis. In patients who have cirrhosis, serum samples had higher IL-33 than samples from healthy controls (p<0.001). In mice, knocking out Il-33 resulted in decreased chemical-, parasite- and biliary-induced hepatic fibrosis compared with no knockout. Next steps could include screening for and evaluating compounds that inhibit IL-33 signaling.

SciBX 6(35); doi:10.1038/scibx.2013.963
Published online Sept. 12, 2013

Patent and licensing information unavailable

Mchedlidze, T. et al. Immunity; published online Aug. 15, 2013;
doi:10.1016/j.immuni.2013.07.018
Contact: Stefan Wirtz, University of Erlangen-Nuremberg, Erlangen, Germany
e-mail:
stefan.wirtz@uk-erlangen.de